Literature DB >> 2037318

Human in vivo-induced spontaneous IgG-secreting cells from tonsil, blood and bone marrow exhibit different phenotype and functional level of maturation.

J A Brieva1, E Roldán, M L De la Sen, C Rodriguez.   

Abstract

The subset of human spontaneous IgG-secretion cells consists of mature B lymphocytes which are capable of active and high rate IgG production in vitro without the need for additional stimuli. Therefore, such a cell subset provides a useful model for studying the terminal stages of B-cell maturation. The present work analyses the phenotypic and functional characteristics of spontaneous IgG secreting cells obtained from tonsil, blood and bone marrow. The tonsilar cell subset was CD9+ CD20+ CD19+ CD38+/-, the blood cell subset CD9- CD20- CD19+ CD38+/- and bone marrow cells were CD9- CD20- CD19+/- CD38+. The three cell subsets required de novo RNA and protein synthesis for IgG secretion to occur. Tonsilar and blood, but not bone marrow, subsets also required DNA synthesis to undergo IgG secretion. Kinetics studies revealed that IgG production by tonsil and blood cells reached a plateau after 3 days of culture. In contrast, the bone marrow cell subset secreted IgG in a linear fashion for 2 weeks. These results indicate that spontaneous IgG-secreting cells from different organs exhibit functional and phenotypic heterogeneity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037318      PMCID: PMC1384381     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies.

Authors:  C Lue; A Tarkowski; J Mestecky
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

2.  Characterization of a circulating subpopulation of spontaneous antitetanus toxoid antibody producing B cells following in vivo booster immunization.

Authors:  R H Stevens; E Macy; C Morrow; A Saxon
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

3.  Disorders of regulatory T cells in patients with selective IgA deficiency and its relationship to associated autoimmune phenomena.

Authors:  E G De la Concha; J L Subiza; G Fontán; D Pascual-Salcedo; J Sequí; A Bootello
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

4.  Antigens on human plasma cells identified by monoclonal antibodies.

Authors:  K C Anderson; E K Park; M P Bates; R C Leonard; R Hardy; S F Schlossman; L M Nadler
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

5.  Phenotypic expression of B-lymphocytes. 1. Identification with monoclonal antibodies in normal lymphoid tissues.

Authors:  S M Hsu; E S Jaffe
Journal:  Am J Pathol       Date:  1984-03       Impact factor: 4.307

Review 6.  The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation.

Authors:  R Benner; W Hijmans; J J Haaijman
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

7.  Expression of cell surface markers after human B lymphocyte activation.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

8.  Antibody synthesis by bone marrow cells in vitro following primary and booster tetanus toxoid immunization in humans.

Authors:  H Kodo; R P Gale; A Saxon
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

9.  In vitro production of anti-influenza virus antibody after intranasal inoculation with cold-adapted influenza virus.

Authors:  R Yarchoan; B R Murphy; W Strober; M L Clements; D L Nelson
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

10.  B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.

Authors:  L M Nadler; K C Anderson; G Marti; M Bates; E Park; J F Daley; S F Schlossman
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

View more
  8 in total

Review 1.  The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications.

Authors:  J Braun; A Saxon; R Wall; S L Morrison
Journal:  West J Med       Date:  1992-08

Review 2.  Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.

Authors:  Falk Hiepe; Thomas Dörner; Anja E Hauser; Bimba F Hoyer; Henrik Mei; Andreas Radbruch
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

3.  Detection and characterization of plasma cells in peripheral blood: correlation of IgE+ plasma cell frequency with IgE serum titre.

Authors:  A Horst; N Hunzelmann; S Arce; M Herber; R A Manz; A Radbruch; R Nischt; J Schmitz; M Assenmacher
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

4.  VLA-4-fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion.

Authors:  E Roldán; A García-Pardo; J A Brieva
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

Review 5.  A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit.

Authors:  Reuben M Tooze
Journal:  Front Immunol       Date:  2013-12-18       Impact factor: 7.561

Review 6.  The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy.

Authors:  Louisa K James
Journal:  Curr Allergy Asthma Rep       Date:  2016-02       Impact factor: 4.806

7.  Network Organization of Antibody Interactions in Sequence and Structure Space: the RADARS Model.

Authors:  József Prechl
Journal:  Antibodies (Basel)       Date:  2020-05-06

8.  Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.

Authors:  Olga Kryštůfková; Sevim Barbasso Helmers; Paulius Venalis; Vivianne Malmström; Eva Lindroos; Jiří Vencovský; Ingrid E Lundberg
Journal:  Arthritis Res Ther       Date:  2014-10-10       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.